CD4 and neoplasm: Secondly, anlotinib can promote the normalization of tumor vasculature through CD4+ T cells, transforming the immunosuppressive tumor microenvironment into an immunostimulatory one, inhibiting tumor growth, and preventing systemic immunosuppression.